Procalcitonin. Usefulness as a biomarker in the diagnosis of neuroendocrine tumors
DOI:
https://doi.org/10.32818/reccmi.a6n2a8Keywords:
procalcitonin, neuroendocrine tumor, prostate.Abstract
Procalcitonin is used in the day-to-day hospital as a biomarker of bacterial infectious pathology. In recent years, its usefulness for the diagnosis of different neuroendocrine tumors has been described. We present the case of a 73-year-old man with a diagnosis of a high-grade neuroendocrine tumor of unknown origin with single and massive liver involvement being compatible, due to the elevated prostatic antigen (PSA), with a high-grade neuroendocrine tumor of prostate origin with visceral involvement and analytically presenting elevated procalcitonin.
Downloads
Metrics
References
- Hoeboer SH, van der Geest PJ, Nieboer D, Groeneveld AB. The diagnostic accuracy of procalcitonin for bacteraemia: a systematic review and meta-analysis. Clin Microbiol Infect. 2015; 21(5): 474-81. doi: https://doi.org/10.1016/j.cmi.2014.12.026.
- Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med. 2008; 36(3): 941-52. doi: https://doi.org/10.1097/CCM.0B013E318165BABB.
- Takahashi K, Ozawa E, Nakao K, Aoki S, Takase Y. Hepatobiliary and Pancreatic: A procalcitonin-secreting and calcitonin-secreting pancreatic neuroendocrine carcinoma. J Gastroenterol Hepatol. 2019; 34(6): 964. doi: https://doi.org/10.1111/jgh.14568.
- Han X, Zhong H, Hong D, Li C, Su H, Xu K. Elevated procalcitonin levels in primary hepatic neuroendocrine carcinoma: Case report and literature review. Medicine (Baltimore). 2020; 99(31): e21210. doi: https://doi.org/10.1097/MD.0000000000021210.
- Fine SW. Neuroendocrine tumors of the prostate. Mod Pathol. 2018; 31(S1): S122-132. doi: https://doi.org/10.1038/modpathol.2017.164.
- Nelson EC, Cambio AJ, Yang JC, Ok JH, Lara PN Jr, Evans CP. Clinical implications of neuroendocrine differentiation in prostate cancer. Prostate Cancer Prostatic Dis. 2007; 10(1): 6-14. doi: https://doi.org/10.1038/sj.pcan.4500922.
- Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011; 65(11): 1180-92. doi: https://doi.org/10.1111/j.1742-1241.2011.02799.x.
- Canat L, Atalay HA, Can O, Alkan İ, Ötünçtemur A. Serum procalcitonin levels in prostate cancer: A new biomarker? Urologia. 2018; 85(2): 46-50. doi: https://doi.org/10.1177/0391560317752600.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Diego Morena, Sara Fernandez, María Martinez, Carolina Campos, Desiree Graziani
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
